Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A recurrent ACAA2 variant causes a dominant syndrome of lipodystrophy, lipomatosis, infantile steatohepatitis, and hypoglycemia.

The Journal of clinical investigation·2025
Same author

Erratum. Gain of Function NOTCH3 Variants Cause Familial Partial Lipodystrophy Due to Activation of Senescence Pathways. Diabetes 2025;74:427-438.

Diabetes·2025
Same author

Minimally invasive radical surgery for gallbladder cancer: a single-unit experience of over 200 patients.

Surgical endoscopy·2025
Same author

A plain language summary of the LOCK IT-100 study of taurolidine/heparin catheter lock solution and catheter-related bloodstream infection in hemodialysis.

Future microbiology·2025
Same author

Ring enhancing lesion on CT scan: metastases or a brain abscess?

BMJ case reports·2025
Same author

Laparoscopic hepaticoduodenostomy for bilioenteric reconstruction: an experience.

Surgical endoscopy·2025

Related Experiment Videos

Anemia associated with chronic heart failure: current concepts.

Ravish Shah1, Anil K Agarwal

  • 1Division of Nephrology, The Ohio State University, Columbus, Ohio 43210, USA. anil.agarwal@osumc.edu

Clinical Interventions in Aging
|February 14, 2013
PubMed
Summary

Anemia frequently complicates heart failure, worsening patient outcomes. Current treatments lack clear guidelines, but intravenous iron shows promise, with new agents needing further study.

Keywords:
anemiachronic kidney diseaseelderly populationheart failure

Related Experiment Videos

Area of Science:

  • Cardiology
  • Hematology

Background:

  • Anemia is a common comorbidity in heart failure (HF) patients.
  • It is linked to adverse clinical outcomes and disease progression.
  • The pathophysiology involves complex interactions including iron deficiency, kidney disease, and inflammation.

Purpose of the Study:

  • To review the current understanding of anemia in heart failure.
  • To discuss existing and emerging therapeutic strategies.
  • To highlight the need for evidence-based treatment guidelines.

Main Methods:

  • Literature review of anemia in heart failure.
  • Analysis of current treatment approaches and their limitations.
  • Evaluation of the role of iron supplementation and erythropoiesis-stimulating agents.
  • Consideration of novel therapeutic agents.

Main Results:

  • Intravenous iron administration benefits both anemic and non-anemic heart failure patients.
  • Erythropoietin-stimulating agents (ESAs) have been used, but evidence for clear guidelines is lacking.
  • Micronutrient deficiencies and blood loss can also contribute to anemia in this population.

Conclusions:

  • Treatment for anemia of heart failure requires defined targets and specific therapies.
  • Further randomized controlled trials are essential to establish robust guidelines for available and novel agents.
  • Addressing anemia is crucial for improving outcomes in heart failure management.